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INTRODUCTION
Despite increasing understanding of pain mechanisms and ongoing research in pain therapy, improved postoperative analgesia is a challenge for anaesthesiologists and every person involved in patient care postoperatively. The efficacy of postoperative pain therapy after major joint replacement surgery is one of the most important factors in functional outcome. Good postoperative analgesia is associated with less postoperative physiological disturbances and improvement in postoperative morbidity and rehabilitation. This paper proposes the epidural application of glucocorticoids as a component of balanced preventive multimodal analgesia for acute postoperative pain relief after knee replacement surgery. An increasing number of publications concerning the use of steroids in acute pain relief has appeared in recent years. The development of adrenocortical physiology and pharmacology has advanced exogenous glucocorticoids to become one of the most widely used classes of drugs in clinical medicine (Schimmer et al., 1996) . Glucocorticoids have powerful anti-inflammatory characteristics (Ontjes et al., 1995; Ferreira et al., 1997; Barnes et al., 1998) . In the last years, several theories about the genomic effects of glucocorticoids have been developed. The inhibition of inflammation involves decreased stability of messenger ribonucleic acid (mRNA) for the genes of inflammatory proteins, such as vascular endothelial growth factor and cyclooxygenase (COX)-2. Glucocorticoid-induced effects that require protein synthesis have about two hours latency of onset; therefore, to have advantages in anti-inflammatory and pain reductive effects, it seems to be necessary to inject glucocorticoids preoperatively. At the same time, there are reports of rapid onset of analgesic and antihyperalgesic effects of glucocorticoids (Romunstad et al., 2004) . It is now accepted that PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 62 (2008) , No. 4/5 (657/658), pp. 182-188. DOI: 10.2478/v10046-008-0020-3 EFFECTS OF DIFFERENT EPIDURAL ANALGESIC COMPOSITIONS ON POSTOPERATIVE PAIN RELIEF AND SYSTEMIC RESPONSE TO SURGERY Iveta Golubovska*, Pçteris Studers*, Inta Jaunalksne**, and Indulis Vanags*** glucocorticoids, in addition to the traditional genomic effects which take hours, show rapid effects by acting on membrane receptors (Falkenstein et al., 2000) . These rapid nongenomic effects of glucocorticoids are due, at least in part, to decreased glutamate release and increased release of g-aminobutyric acid and endocannabinnoids (Di et al., 2005) . Recent work suggests that glucocorticoids can have rapid effects on inflammation that are not mediated by changes in gene expression. The best described nongenomic mechanism involves the activation of endothelial nitric oxide synthetase (eNOS) (Hafezi-Moghadam et al., 2002) . Small proteins called cytokines have a major role in the inflammatory response to surgery, trauma and pain mechanisms. They have local effect of mediating and maintaining the inflammatory response to tissue injury and they also initiate some of the systemic changes that may occur. The main cytokines released are interleukin-1 (IL-1), tumour necrosing factor (TNF-a) and interleukin-6 (IL-6); they are responsible for inducing the systemic changes known as the acute phase response. Administration of glucocorticoids after incision suppresses the release of proinflammatory cytokines. Varying doses of glucocorticoids do not lead simply to varying degrees of inflammation suppression; considerably more, they can exert a full range of effects from permissive to stimulatory to suppressive (Yeager et al., 2004) .
Glucocorticoids are efficacious in perioperative management and particularly in postoperative pain relief as adjuvant analgesics (Watanabe et al., 1994) . Glucocorticoids have potent anti-inflammatory effects and reduce pain and swelling after oral operations (Skjelberd et al., 1982) , orthopaedic and spinal operations (Holte et al., 2002) , laparoscopic (Bisgaard et al., 2003) , major abdominal (Schulze et al., 1992 (Schulze et al., , 1998 and artroscopic procedures (Kizilkaya et al., 2005) as well as after lumbar disc surgery (Lavyne et al., 1992; Glasser et al., 1993; Langmayr et al., 1995) . There are many publications supporting high doses of intravenous glucocorticoids during major cardiac, abdominal and orthopaedic surgery (Nagelshmidt et al., 1999; Sauerland et al., 2000; Yeager et al., 2004 Yeager et al., , 2005 , which decrease stress response to major surgery. We have found recent observational studies (Marinangeli et al., 2002; Gilron et al., 2004; Salerno et al., 2006 , Kehlet, 2007 suggesting wider application of glucocorticoids for postoperative pain relief. Findings in experimental pain models (Romunstad et al., 2004; Stubhaug et al., 2007) help to understand the research results on the effects of methylprednisolone on reduction of pain, postoperative nausea and vomiting, fatigue and late wound hyperesthesia, as well as sustained analgesic effect and reduced opioid requirements for 1-3 days after surgery (Romunstad et al., 2004 (Romunstad et al., , 2006 .
Patients who have a herniated disk, spinal stenosis or failed back surgery may benefit from epidural steroid injection with methylprednisolone acetate (Manchikanti et al., 2002; Singh et al., 2002) . Reports on thousands of patients indicate that epidural glucocorticoid injections are relatively straightforward and safe in the treatment of back pain (Carette et al., 1997) .
Anaesthesiologists began to use steroids epidurally mostly for backache treatment common after surgery or epidural needle insertion. Soon after, they discovered significant reduction in postoperative analgesia requirements. McNeil et al. (1995) administered epidurally separately saline solution, morphine, methylprednisolone and a combination of morphine and methylprednisolone for pain reduction after spinal stenosis surgery or herniated intervertebral disc. Wang et al. (1998) gave dexametasone epidurally after muiltiple epidural needle insertion. The severity and duration of postepidural backache also significantly decreased in those patients. Since patients complained about back pain after surgical interventions-mostly related to bad positioning or pre-existing discogenic disease-on the supposition that postoperative pain should be treated preventively, patients received 1 mg morphine with 80 mg of methylprednisolone epidurally directly after surgery (Joos et al., 1993) . Preoperative epidural administration of dexamethasone 5 mg, with or without bupivacaine, reduced postoperative pain and morphine consumption following laparoscopic cholecistectomy (Thomas et al., 2006) . Studies about epidural methylprednisolone-morphine compositions in orthopaedic knee surgery showed comparable or even superior analgesic effect with bupivacaine-morphine mixture .
We can be quite certain in saying that methylprednisolone suspension has no neurotoxic effect on normal nerves and in the epidural space (Johansson et al., 1995; Delaney et al., 1980) . The aim of our study is to compare pain relief by epidural route of analgesia, using different combinations that include glucocorticoids (methylprednisolone), with habitual composition of bupivacaine-morphine mixture, in regard to analgesic and anti-inflammatory properties of glucocorticoids.
The objectives for our research were: 1) To determine whether perioperative use of epidural methylprednisolone is a sufficient analgesic, when given in small doses of opioids or without them, to achieve an acceptable pain verbal rating score (0-4).
2) To determine whether perioperative use of epidural methylprednisolone can improve endocrine and immune response to surgery.
3) To compare the quality of pain relief and side effects of methylprednisolone-morphine, methylprednisolone-fentanyl combinations and methylprednisolone with bupivacainemorphine combination after knee replacement surgery.
MATERIALS AND METHODS
The study was performed at the Department of Anaesthesiology and Orthopaedics of the Hospital of Traumatology and Orthopaedics. The Ethics Committee of Rîga Stradiòð University approved the study protocols. Informed consent was obtained from all patients. Prospective randomised single-blind trial was conducted from November 2006 to May 2008. A total of 135 patients undergoing knee replacement surgery were included in this study. Patients with diabetes mellitus, infectious problems, rheumatoid arthritis, gastrointestinal ulcerations and those who used glucocorticoids were excluded from the study. Patients were randomly assigned to one of the four study groups. Randomisation was performed in active concurrent control groups.
Patients of Group I received glucocorticoid methylprednisolone succinate and long-acting opioid morphine hydrochloride (n = 33).
Patients of Group II received local anaesthetic bupivacaine hydrochloride and morphine hydrochloride (n = 41).
Patients of Group III received methylprednisolone succinate and short-acting opioid fentanyl (n = 31).
Group IV received methylprednisolone succinate (n = 30).
Combined spinal-epidural anaesthesia (CSEA) was performed to all patients. Spinal bupivacaine 0.5% was injected intratecally for surgical analgesia. At the end of surgery and during their stay in the postanaesthesia care unit (PACU), patients received different epidural analgesic compositions in accordance with the protocol and time schedules (See Table 1 ). For each recruited patient in groups I-IV, a trained nurse followed the instructions and prepared the study drugs. All of the study preparations were masked by dilution to the same volume of saline (10 ml). If analgesia was unsatisfactory, the rescue analgesic was bupivacaine 0.5% 5 ml (25 mg) epidurally. Rescue medication was given on patient request or if pain exceeded 4 by a 10-point numeral verbal rating scale (NVRS).
Sensory level, motor blockade, pain score, time until the first rescue analgesic, the amount of additional bupivacaine, mean arterial pressure and pulse rate were assessed after introduction for 24 hours. Changes of glucose, C-reactive protein, IL-6 and cortisol were measured before incision and 24 h after the first epidural injection. Side effects were registered. Patients assessed their experience of postoperative pain at rest by indicating a number on the eleven-point NVRS between the extremes 0 cm-no pain and 10 cmthe worst pain imaginable at 0, 2, 4, 6, 8, 12, 16, 20 
RESULTS
Six patients were excluded from study due to accidental evacuation of epidural catheter or major motor blockade. Statistical analysis was performed for 129 patients. Patients in all study groups were statistically comparable (P > 0.05) (See Table 2 ).
Although patients in all treatment groups had very acceptable pain scores during the entire period of measurements, the score differed among treatment groups. 24-hour pain intensity was quite similar in all groups, with the lowest score in Group I (see Fig. 1 ). Regarding the intensity of pain at each observation time, Group I succeeded better than others in the periods just before the first planned epidural injection and during night sleep. Multivariate NVRS at time 3 (6 hours from the first epidural injection) differed among groups: I = 0.5 ± 0.6; II = 1.2 ± 0.9; III = 1.3 ±1.1; IV=1.4 ± 0.8 points (P < 0.001). Multivariate NVRS at time 5 (which means 12 hours after the first epidural injection): I = 0.8 ± 1.1; II = 1.0 ± 1.0; III =1.4 ± 1.4; IV = 1.1±1.0 points (P < 0.05). The mean pain score for all measurements across times did not differ significantly (P > 0.05) between groups: Group I was 0.6 ± 0.4, in Group II -0.8 ± 0.4, in Group III 0.9 ± 0.5, and in Group IV 0.8 ± 0.4. The patients in Group I required significantly less additional bupivacaine administered epidurally. The number of additional 2), 0-5 times in Group IV (mean 2.2 ± 1.2) (P < 0.05). During the observation period, 15 patients (47%) did not require epidural bupivacaine injections for pain relief in Group I, while only two patients obtained such prolonged pain relief in Groups III and IV (9.4%, 6.2%). The amount of bupivacaine required for breakthrough pain to reach sufficient analgesia was significantly different in all groups. In Group I, the consumption of additional bupivacaine amid patients who needed it during the first 24 hours postoperatively was 31.0 ± 10.9 mg, in Group II 40.5 ± 19.4 mg, in Group III 58.6 ± 26.4 mg, and in Group IV 57.4 ± 27.5 mg (mean± SD, P < 0.05) (see Table 3 ). There were no significant differences in time until the first rescue analgesic among groups in patients who needed them.
Not many cardiovascular, neurological and other complications were observed. One patient from Group II died from myocardial infarction on the fifth postoperative day. One patient from Group I developed aseptic inflammation in the knee six months after surgery. The problem was resolved by means of conservative methods. Minor side effects were not statistically different among the groups.
Overall satisfaction rate was very good: 8.5 ± 1.2 points. The mean satisfaction rates were: 8.7 ± 1.0 in Group I, 8.6 ± 1.3 in Group II, 8.8 ± 1.0 in Group III, 8.7 ± 1.0 in Group IV (mean ± SD, P > 0.05).
Regarding anti-inflammatory and hormonal responses to analgesia, we observed a significant difference in IL-6 and CRP postoperative production among the study groups. The increase was similar in the methylprednisolone groups (I, III, IV), while being significantly higher in Group II (see Table 4 ). The mean IL-6 levels were significantly lower in the methylprednisolone groups compared to bupivacaine group on postoperative day I (P < 0.001). There was an increase in the plasma concentration of C-reactive protein in all groups following surgery. The mean C-reactive protein levels were significantly higher in the bupivacaine group compared to methylprednisolone groups on postoperative day I (P < 0.05). We performed Pearson's correlation analysis between IL-6 and C-reactive protein levels in the different treatment groups and found significant correlations between IL-6 and C-reactive protein concentrations in Groups I, II and III, but not in Group IV. Cortisol production decreased significantly postoperatively in the methylprednisolone groups (P < 0.05) (see Table 4 ). There was no statistically significant difference in glucose levels before and after surgery among groups, except Group IV (See Table 4 ).
DISCUSSION
We compared our study with other outcomes after knee replacement surgery, using epidural analgesia. Muldoon et al. (1998) compared 0.2% ropivacaine or 0.2% bupivacaine by epidural infusion for 24 h after operation. Pain by visual analogue scale (VAS) at rest was low in both groups; the median VAS was 0-13.3 mm (by 100 mm VAS) for the ropivacaine group and 0-0.5 mm for the bupivacaine group. Over 24 h of infusion, the estimated (ropivacaine-bupivacaine) difference in wound pain at rest was 5.6 mm (P < 0.05) and on passive movement-11.6 mm (P < 0.05). Himmelseher et al. (2001) added ketamine to epidural injections prior to surgery. After lumbar epidural anaesthesia with ropivacaine (10 mg/ml, 10-20 ml), patients received 0.9% epidural saline or 0.25 mg/kg epidural S(+)-ketamin 10 min before surgical incision. During the first 8 h after surgery, VAS pain rating was similar among groups; nevertheless, the mean VAS for the ketamin group was below 1, whereas for the ropivacaine group-between 1 and 3 at rest. Buvendranan et al. (2006) studied the effects of COX-2 inhibitors on pain management after total knee replacement. CSEA was performed, and the infusion of fentanyl and bupivacaine was started, allowing patients to give themselves bolus doses at their discretion to maintain VAS between 2 and 4. The research group received additional rofecoxib. Postoperative median pain scores were: 3.5 (2.7-4.3) in the patient-controlled epidural analgesia group; 2.2 (1.4-3.2) in the rofecoxib group. Pain scores were significantly lower in our study.
Some studies have not found analgesic properties of epidural glucocorticoids. Lavyne et al. (1992) reported that patients undergoing microdiscectomy, who received epidural methylprednisolone after surgery, did not have reduction of pain compared to the control group. Blanloeil et al. (2001) compared epidural infusion of methylprednisolone 1.5 mg/kg and placebo after posterolateral thoracotomy. Additional morphine analgesia was administered by intravenous patient-controlled analgesia. There was no significant difference for morphine requirements between the groups. Reikeras et al.
studied glucocorticoids and cytokine production during surgery in orthopaedic patients, administering high doses of methylprednisolone intravenously (10 mg/kg) and did not find any significant effect of glucocorticoids on postoperative pain. In major abdominal or thoracic surgery, the analgesic and other outcome effects of perioperative glucocorticoids are promising but still debatable; therefore, no definite conclusions can be drawn yet. Studies on major abdominal surgery (Apfel et al., 2004) have not been able to document any definite analgesic effect of glucocorticoids.
The difference in pain among groups did not differ much 24 hours after surgery with clearly better result in Group I. The postoperative period may reflect the interval required for the sensitising effects of surgery to become fixed, or it may reflect peripheral inputs from the operated knee, obscuring the spinal component of nociception in the earlier postsurgical period. In particular, the crucial time interval appears to be from the first minutes to hours after surgery, and then there is a second phase of inflammatory injury with interleukins and acute phase proteins rising up. We cannot decisively state that preventive analgesia was shown. We can only speculate that methylprednisolone blocked pain sensitisation during the entire observation period, while its antinociceptive effects were accomplished by the action of morphine and bupivacaine during the first postoperative hours.
On the other hand, pain did not become clinically relevant before patient mobilisation was started. We suggest that the use of small doses of epidural methylprednisolone with morphine before pain begins may decrease injury-induced pain sensitisation, and thus provide better analgesia in the postoperative period than that achieved with a dose of local anaesthetics with morphine in the epidural space.
The concomitant administration of methylprednisolone and morphine results in a synergistic analgesic effect. Sustained postoperative opioid sparring effect and pain relief continuing for three days after one single dose of glucocorticoids (methylprednisolone or dexamethasone) have been reported (Romundstad et al., 2004) . A prolonged opioid sparring effect, continuing for at least 72 hours, indicates a prolonged effect of methylprednisolone on postoperative inflammatory pain, which could be explained by the duration of biological anti-inflammatory activity of methylprednisolone-estimated to be about 36 hours after intravenous injection (Holte et al., 2004) , although it might be different after epidural injection.
We did not find any similar studies about epidural glucocorticoids and attenuated neuroendocrine and immune response. Reikeras et al. (2008) carried out a study of intravenous high-dose methylprednisolone (10 mg/kg) in orthopaedic surgery and found that glucocorticoids significantly reduced the increases in IL-6 and C-reactive protein.
The imbalance between proinflammatory and anti-inflammatory cytokines determines the development of stress response to surgery and should help the physician to compose a therapeutic strategy. In fact, recent clinical studies have shown that both the initial uncontrolled hyperinflammation and the continued cell-mediated immunosuppression represent primary targets to counteract the post-surgery immune dysfunction (Menger et al., 2004) . There are many studies investigating the role of IL-6 in the development of pain, and it is well reviewed that IL-6 is related to the development of pain and that intrathecal anti-IL-6 antibody will attenuate this reaction (De Leo et al., 1996) . Pain is transmitted from the periphery to higher brain areas, from where the pain messages can be either suppressed (analgesia), relayed unaltered, or amplified (hyperalgesia). Pain modulation occurs in the dorsal horns of the spinal cord, where peripheral nerves relay sensory information to pain transmission neurons. Both analgesia and hyperalgesia originate at the point where the periphery meets the CNS. Neutralizing IL-6 or changes in the IL-6 pathway alter the perception of pain. IL-6 induces pain by releasing COX products and inducing arachidonic acid release. This mechanism can be aborted by glucocorticoids. Injecting glucocorticoids epidurally influence IL-6 production both generally and locally; notably, only very small amounts are needed for good effect.
Pearson's correlation test did not show any statistically significant correlation between IL-6 concentration and the mean pain intensity, which might be explained by wrong timing. In any case, it is difficult to interpret the absence of correlation between IL-6 level and intensity of pain from one measurement. We chose a 24-hour time interval because it was described as the peak level of IL-6 and C-reactive protein after major orthopaedic surgery (both hip and knee) in some literature (Hall et al., 2000) and major orthopaedic surgery of spine in others (Reikeras et al., 2008 ).
In conclusion:
1) Epidural analgesia produced reliable pain relief in all study groups. Patients were highly satisfied with knee surgery performed under epidural analgesia. However, significantly better results were achieved when using the combination of methylprednisolone and morphine (Group I).
2) Epidural methylprednisolone 80 mg/24 h is effective as a part of multimodal preventive postoperative analgesia after major joint replacement surgery. Compared to habitual local anaesthetics and opioid mixture, it shows a similar or even better analgesic effect (in combination with morphine).
3) Adding fentanyl in epidural mixtures had only a minor effect on postoperative analgesia after knee replacement surgery with no significant difference from that achieved with addition of saline.
4) Epidural methylprednisolone has marked morphine sparring effect.
5) Epidural methylprednisolone has marked anti-inflammatory and immunomodulatory potential. The altered IL-6, C-reactive protein and cortisol values among the groups may be a direct effect of methylprednisolone, considering that the same type of surgery-i.e. producing similar degrees of tissue damage-and anaesthetic regimens were used.
DAÞÂDU PÇCOPERÂCIJAS EPIDURÂLO ANALGÇZIJAS KOMPOZÎCIJU IETEKME UZ ATSÂPINÂÐANU UN ATBILDI ÍIRURÌISKAJAM STRESAM PÇC CEÏA ENDOPROTEZÇÐANAS OPERÂCIJÂM Neraugoties uz sasniegumiem pçdçjos gados, akûtâs pçcoperâcijas sâpes ir visbieþâkâ pacientu sûdzîba pçc íirurìiskas iejaukðanâs, taèu tâs ir potenciâli visvairâk ietekmçjamas perioperatîvajâ periodâ. Mûsu pçtîjuma mçríis bija salîdzinât epidurâlo atsâpinâðanu pçc ceïa endoprotezçðanas operâcijâm, izmantojot daþâdas medikamentu kompozîcijas. Mçs salîdzinâjâm grupas, kuru kompozîcijas ietvçra glikokortikoîdu metilprednizolonu kombinâcijâs ar daþâdiem opioîdiem un bez tiem ar ierasto lokâlâ anestçtiía bupivakaîna un morfîna kompozîciju un pçtîjâm to ietekmi uz pçcoperâcijas atsâpinâðanu un neiroendokrîno un imûno atbildi íirurìiskajam stresam. Pçtîjumu pabeidza 129 pacienti èetrâs terapijas grupâs. I grupas pacienti epidurâli saòçma glikokortikoîdu metilprednizolona sukcinâtu un ilgstoðas darbîbas opioîdu morfîna hidrohlorîdu, II grupas pacienti saòçma lokâlo anestçtiíi bupivakaîna hidrohlorîdu un morfîna hidrohlorîdu, III grupas pacienti saòçma metilprednizolona sukcinâtu un fentanîlu, IV grupas pacienti saòçma metilprednizolona sukcinâtu. Atsâpinâðana bija ïoti laba visâs terapijas grupâs, bet metilprednizolona-morfîna grupâ mçs ieguvâm statistiski ievçrojami labâkus rezultâtus. Epidurâlais metilprednizolons devâ 80 mg/dn atklâjâs kâ efektîva multimodâlâs preventîvâs atsâpinâðanas sastâvdaïa pçc ceïa endoprotezçðanas operâcijâm. Salîdzinot ar ierasto bupivakaîna-morfîna kompozîciju, ir pierâdîts lîdzîgs vai pat vçl labâks efekts. Epidurâlais metilprednizolons ir arî pierâdîjis savas imûnmodulçjoðâs un pretiekaisuma îpaðîbas, ietekmçjot akûtâs pçcoperâcijas iekaisîgâs fâzes mediatorus -interleikînu-6 un C-reaktîvo olbaltumu un samazinot stresa hormona kortizola lîmeni pçcoperâcijas periodâ. Ðî pçtîjuma novitâte ir glikokortikoîdu epidurâlâ izmantoðana tieði akûto pçcoperâcijas sâpju samazinâðanai ikdienas darbâ. Attîstot pçtîjumus par metilprednizolona pretiekaisuma un imûnmodulçjoðâm îpaðîbâm, mçs vçlçtos uzlabot pacientu rehabilitâciju pçcoperâcijas periodâ.
